Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Financial News

Atreca’s $125M round paves way for first immunotherapy into clinic

September 12, 2018 4:01 AM UTC

Atreca Inc. (Redwood City, Calif.) raised $125 million in a series C round led by an undisclosed U.S.-based healthcare fund, clearing the way for the company to move its first cancer immunotherapy into the clinic.

Fellow existing investors Wellington Capital and Cormorant Asset Management, as well as new investors Aisling Capital, Boxer Capital of the Tavistock Group, EcoR1 Capital, Redmile Group, Samsara BioCapital and funds managed by Tekla Capital Management also participated...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Atreca Inc.